DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease

David M. Mahvi, H. F. Seigler, William C. Meyers, Holger Kalthoff, Wolff H. Schmiegel, Richard S. Metzgar*

*Corresponding author for this work

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Previous studies have shown that the DU-PAN-2 antigen is elevated in, 70% of serum samples obtained from pancreatic adenocarcinoma patients, and within the normal range (<400 U/ml) in 99% of normal subjects. In this study, the DU-PAN-2 antigen level of the serum and pancreatic ductal fluid in patients with malignant pancreatic disease were compared to antigen levels in patients with benign pancreatic diseases. Six percent of patients with chronic pancreatitis and 13% of patients with severe acute pancreatitis had elevated DU-PAN-2 antigen levels in their sera. Pancreatic ductal fluid DU-PAN-2 levels were elevated in 33% (11 of 33) of patients with pancreatic adenocarcinomas, whereas 16% (5 of 31) of patients with chronic pancreatitis and 38% (8 of 21) of control patients had elevated secretion levels. Unlike DU-PAN-2, the tumor markers carcinoembryonic antigen (CEA) and carcinoma (CA) 19-9 were elevated in 90 and 100%, respectively, of secretions of patients with pancreatic adenocarcinoma. However, CEA and CA 19-9 ductal fluid levels were also elevated in patients with chronic pancreatitis (CEA: 61%; CA 19-9: 85%), and therefore these markers are not helpful in distinguishing benign from malignant pancreatic disease. The physiologic implications of elevated DU-PAN-2 serum antigen levels in patients with normal ductal fluid DU-PAN-2 levels are discussed.

Original languageEnglish (US)
Pages (from-to)488-493
Number of pages6
JournalPancreas
Volume3
Issue number4
DOIs
StatePublished - Aug 1988

Fingerprint

Pancreatic Diseases
Serum
Carcinoembryonic Antigen
Chronic Pancreatitis
Antigens
Adenocarcinoma
Carcinoma
Differentiation Antigens
Neoplasm Antigens
Tumor Biomarkers
Pancreatitis
Reference Values

Keywords

  • DU-PAN-2 antigen
  • Pancreatic adenocarcinoma
  • Pancreatic ductal fluid
  • Serum

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Mahvi, D. M., Seigler, H. F., Meyers, W. C., Kalthoff, H., Schmiegel, W. H., & Metzgar, R. S. (1988). DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease. Pancreas, 3(4), 488-493. https://doi.org/10.1097/00006676-198808000-00020
Mahvi, David M. ; Seigler, H. F. ; Meyers, William C. ; Kalthoff, Holger ; Schmiegel, Wolff H. ; Metzgar, Richard S. / DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease. In: Pancreas. 1988 ; Vol. 3, No. 4. pp. 488-493.
@article{72c3b1c325964826bc131d0eba988487,
title = "DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease",
abstract = "Previous studies have shown that the DU-PAN-2 antigen is elevated in, 70{\%} of serum samples obtained from pancreatic adenocarcinoma patients, and within the normal range (<400 U/ml) in 99{\%} of normal subjects. In this study, the DU-PAN-2 antigen level of the serum and pancreatic ductal fluid in patients with malignant pancreatic disease were compared to antigen levels in patients with benign pancreatic diseases. Six percent of patients with chronic pancreatitis and 13{\%} of patients with severe acute pancreatitis had elevated DU-PAN-2 antigen levels in their sera. Pancreatic ductal fluid DU-PAN-2 levels were elevated in 33{\%} (11 of 33) of patients with pancreatic adenocarcinomas, whereas 16{\%} (5 of 31) of patients with chronic pancreatitis and 38{\%} (8 of 21) of control patients had elevated secretion levels. Unlike DU-PAN-2, the tumor markers carcinoembryonic antigen (CEA) and carcinoma (CA) 19-9 were elevated in 90 and 100{\%}, respectively, of secretions of patients with pancreatic adenocarcinoma. However, CEA and CA 19-9 ductal fluid levels were also elevated in patients with chronic pancreatitis (CEA: 61{\%}; CA 19-9: 85{\%}), and therefore these markers are not helpful in distinguishing benign from malignant pancreatic disease. The physiologic implications of elevated DU-PAN-2 serum antigen levels in patients with normal ductal fluid DU-PAN-2 levels are discussed.",
keywords = "DU-PAN-2 antigen, Pancreatic adenocarcinoma, Pancreatic ductal fluid, Serum",
author = "Mahvi, {David M.} and Seigler, {H. F.} and Meyers, {William C.} and Holger Kalthoff and Schmiegel, {Wolff H.} and Metzgar, {Richard S.}",
year = "1988",
month = "8",
doi = "10.1097/00006676-198808000-00020",
language = "English (US)",
volume = "3",
pages = "488--493",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Mahvi, DM, Seigler, HF, Meyers, WC, Kalthoff, H, Schmiegel, WH & Metzgar, RS 1988, 'DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease', Pancreas, vol. 3, no. 4, pp. 488-493. https://doi.org/10.1097/00006676-198808000-00020

DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease. / Mahvi, David M.; Seigler, H. F.; Meyers, William C.; Kalthoff, Holger; Schmiegel, Wolff H.; Metzgar, Richard S.

In: Pancreas, Vol. 3, No. 4, 08.1988, p. 488-493.

Research output: Contribution to journalArticle

TY - JOUR

T1 - DU-PAN-2 levels in serum and pancreatic ductal fluids of patients with benign and malignant pancreatic disease

AU - Mahvi, David M.

AU - Seigler, H. F.

AU - Meyers, William C.

AU - Kalthoff, Holger

AU - Schmiegel, Wolff H.

AU - Metzgar, Richard S.

PY - 1988/8

Y1 - 1988/8

N2 - Previous studies have shown that the DU-PAN-2 antigen is elevated in, 70% of serum samples obtained from pancreatic adenocarcinoma patients, and within the normal range (<400 U/ml) in 99% of normal subjects. In this study, the DU-PAN-2 antigen level of the serum and pancreatic ductal fluid in patients with malignant pancreatic disease were compared to antigen levels in patients with benign pancreatic diseases. Six percent of patients with chronic pancreatitis and 13% of patients with severe acute pancreatitis had elevated DU-PAN-2 antigen levels in their sera. Pancreatic ductal fluid DU-PAN-2 levels were elevated in 33% (11 of 33) of patients with pancreatic adenocarcinomas, whereas 16% (5 of 31) of patients with chronic pancreatitis and 38% (8 of 21) of control patients had elevated secretion levels. Unlike DU-PAN-2, the tumor markers carcinoembryonic antigen (CEA) and carcinoma (CA) 19-9 were elevated in 90 and 100%, respectively, of secretions of patients with pancreatic adenocarcinoma. However, CEA and CA 19-9 ductal fluid levels were also elevated in patients with chronic pancreatitis (CEA: 61%; CA 19-9: 85%), and therefore these markers are not helpful in distinguishing benign from malignant pancreatic disease. The physiologic implications of elevated DU-PAN-2 serum antigen levels in patients with normal ductal fluid DU-PAN-2 levels are discussed.

AB - Previous studies have shown that the DU-PAN-2 antigen is elevated in, 70% of serum samples obtained from pancreatic adenocarcinoma patients, and within the normal range (<400 U/ml) in 99% of normal subjects. In this study, the DU-PAN-2 antigen level of the serum and pancreatic ductal fluid in patients with malignant pancreatic disease were compared to antigen levels in patients with benign pancreatic diseases. Six percent of patients with chronic pancreatitis and 13% of patients with severe acute pancreatitis had elevated DU-PAN-2 antigen levels in their sera. Pancreatic ductal fluid DU-PAN-2 levels were elevated in 33% (11 of 33) of patients with pancreatic adenocarcinomas, whereas 16% (5 of 31) of patients with chronic pancreatitis and 38% (8 of 21) of control patients had elevated secretion levels. Unlike DU-PAN-2, the tumor markers carcinoembryonic antigen (CEA) and carcinoma (CA) 19-9 were elevated in 90 and 100%, respectively, of secretions of patients with pancreatic adenocarcinoma. However, CEA and CA 19-9 ductal fluid levels were also elevated in patients with chronic pancreatitis (CEA: 61%; CA 19-9: 85%), and therefore these markers are not helpful in distinguishing benign from malignant pancreatic disease. The physiologic implications of elevated DU-PAN-2 serum antigen levels in patients with normal ductal fluid DU-PAN-2 levels are discussed.

KW - DU-PAN-2 antigen

KW - Pancreatic adenocarcinoma

KW - Pancreatic ductal fluid

KW - Serum

UR - http://www.scopus.com/inward/record.url?scp=0024235401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024235401&partnerID=8YFLogxK

U2 - 10.1097/00006676-198808000-00020

DO - 10.1097/00006676-198808000-00020

M3 - Article

C2 - 3174610

AN - SCOPUS:0024235401

VL - 3

SP - 488

EP - 493

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 4

ER -